Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors

A report from the Children's Oncology Group

C. Kretschmar, Lawrence R Kleinberg, M. Greenberg, P. Burger, Emi Holmes, M. Wharam

Research output: Contribution to journalArticle

Abstract

Background. This Phase II study was designed to determine response to chemotherapy and survival after response-based radiation (RT) in children with CNS germ cell tumors. Procedure. Children with germinomas and normal markers received cisplatin 100 mg/m2 + etoposide, alternating with vincristine + cyclophosphamide (CPM) 2 g/m2/d, for four cycles. Children with nongerminomatous tumors or with abnormal markers received doubled doses of cisplatin and CPM. For germinoma patients in complete response (CR), RT was decreased from 50.4 to 30.6 Gy. High-risk patients received neuraxis RT: 50.4 Cy local + 30.6 Gy neuraxis in CR; 54 Gy local + 36 Gy if less than CR. Results. Of 12 germinoma patients, 4 had cerebrospinal fluid (CSF) human chorionic gonadotropin (HCG) 6.9-21 mlU/ml. Of 14 nongerminomatous patients, HCG in serum or CSF was >50 mlU/ml in 9, α-fetoprotein (AFP) abnormal in 9. Four germinoma patients attained CR, six PR, one SD, one not evaluable after resection. Two nongerminomatous patients had CR, three PR, three SD, one PD, four not evaluable after resection; one inadequately treated patient had progressive disease (PD). Both PD patients died; one SD patient died during a seizure. Eleven germinoma patients are PF at median 66 months; one patient in CR refused RT, had PD at 10 months, received RT, and was PF at 56 months. Eleven of 14 nongerminomatous patients were PF at median 58 months. Conclusion. Response (germinoma, 91%; nongerminomatous, 55%) and survival are encouraging after this regimen plus response-based RT.

Original languageEnglish (US)
Pages (from-to)285-291
Number of pages7
JournalPediatric Blood and Cancer
Volume48
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Nervous System Neoplasms
Germ Cell and Embryonal Neoplasms
Radiotherapy
Central Nervous System
Germinoma
Radiation
Drug Therapy
Chorionic Gonadotropin
Cyclophosphamide
Cisplatin
Cerebrospinal Fluid
Fetal Proteins
Survival
Vincristine
Etoposide

Keywords

  • Brain tumors
  • Chemotherapy
  • Germinoma

ASJC Scopus subject areas

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors : A report from the Children's Oncology Group. / Kretschmar, C.; Kleinberg, Lawrence R; Greenberg, M.; Burger, P.; Holmes, Emi; Wharam, M.

In: Pediatric Blood and Cancer, Vol. 48, No. 3, 03.2007, p. 285-291.

Research output: Contribution to journalArticle

@article{9bb3ab221efe45498f52da92ab4cff90,
title = "Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: A report from the Children's Oncology Group",
abstract = "Background. This Phase II study was designed to determine response to chemotherapy and survival after response-based radiation (RT) in children with CNS germ cell tumors. Procedure. Children with germinomas and normal markers received cisplatin 100 mg/m2 + etoposide, alternating with vincristine + cyclophosphamide (CPM) 2 g/m2/d, for four cycles. Children with nongerminomatous tumors or with abnormal markers received doubled doses of cisplatin and CPM. For germinoma patients in complete response (CR), RT was decreased from 50.4 to 30.6 Gy. High-risk patients received neuraxis RT: 50.4 Cy local + 30.6 Gy neuraxis in CR; 54 Gy local + 36 Gy if less than CR. Results. Of 12 germinoma patients, 4 had cerebrospinal fluid (CSF) human chorionic gonadotropin (HCG) 6.9-21 mlU/ml. Of 14 nongerminomatous patients, HCG in serum or CSF was >50 mlU/ml in 9, α-fetoprotein (AFP) abnormal in 9. Four germinoma patients attained CR, six PR, one SD, one not evaluable after resection. Two nongerminomatous patients had CR, three PR, three SD, one PD, four not evaluable after resection; one inadequately treated patient had progressive disease (PD). Both PD patients died; one SD patient died during a seizure. Eleven germinoma patients are PF at median 66 months; one patient in CR refused RT, had PD at 10 months, received RT, and was PF at 56 months. Eleven of 14 nongerminomatous patients were PF at median 58 months. Conclusion. Response (germinoma, 91{\%}; nongerminomatous, 55{\%}) and survival are encouraging after this regimen plus response-based RT.",
keywords = "Brain tumors, Chemotherapy, Germinoma",
author = "C. Kretschmar and Kleinberg, {Lawrence R} and M. Greenberg and P. Burger and Emi Holmes and M. Wharam",
year = "2007",
month = "3",
doi = "10.1002/pbc.20815",
language = "English (US)",
volume = "48",
pages = "285--291",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors

T2 - A report from the Children's Oncology Group

AU - Kretschmar, C.

AU - Kleinberg, Lawrence R

AU - Greenberg, M.

AU - Burger, P.

AU - Holmes, Emi

AU - Wharam, M.

PY - 2007/3

Y1 - 2007/3

N2 - Background. This Phase II study was designed to determine response to chemotherapy and survival after response-based radiation (RT) in children with CNS germ cell tumors. Procedure. Children with germinomas and normal markers received cisplatin 100 mg/m2 + etoposide, alternating with vincristine + cyclophosphamide (CPM) 2 g/m2/d, for four cycles. Children with nongerminomatous tumors or with abnormal markers received doubled doses of cisplatin and CPM. For germinoma patients in complete response (CR), RT was decreased from 50.4 to 30.6 Gy. High-risk patients received neuraxis RT: 50.4 Cy local + 30.6 Gy neuraxis in CR; 54 Gy local + 36 Gy if less than CR. Results. Of 12 germinoma patients, 4 had cerebrospinal fluid (CSF) human chorionic gonadotropin (HCG) 6.9-21 mlU/ml. Of 14 nongerminomatous patients, HCG in serum or CSF was >50 mlU/ml in 9, α-fetoprotein (AFP) abnormal in 9. Four germinoma patients attained CR, six PR, one SD, one not evaluable after resection. Two nongerminomatous patients had CR, three PR, three SD, one PD, four not evaluable after resection; one inadequately treated patient had progressive disease (PD). Both PD patients died; one SD patient died during a seizure. Eleven germinoma patients are PF at median 66 months; one patient in CR refused RT, had PD at 10 months, received RT, and was PF at 56 months. Eleven of 14 nongerminomatous patients were PF at median 58 months. Conclusion. Response (germinoma, 91%; nongerminomatous, 55%) and survival are encouraging after this regimen plus response-based RT.

AB - Background. This Phase II study was designed to determine response to chemotherapy and survival after response-based radiation (RT) in children with CNS germ cell tumors. Procedure. Children with germinomas and normal markers received cisplatin 100 mg/m2 + etoposide, alternating with vincristine + cyclophosphamide (CPM) 2 g/m2/d, for four cycles. Children with nongerminomatous tumors or with abnormal markers received doubled doses of cisplatin and CPM. For germinoma patients in complete response (CR), RT was decreased from 50.4 to 30.6 Gy. High-risk patients received neuraxis RT: 50.4 Cy local + 30.6 Gy neuraxis in CR; 54 Gy local + 36 Gy if less than CR. Results. Of 12 germinoma patients, 4 had cerebrospinal fluid (CSF) human chorionic gonadotropin (HCG) 6.9-21 mlU/ml. Of 14 nongerminomatous patients, HCG in serum or CSF was >50 mlU/ml in 9, α-fetoprotein (AFP) abnormal in 9. Four germinoma patients attained CR, six PR, one SD, one not evaluable after resection. Two nongerminomatous patients had CR, three PR, three SD, one PD, four not evaluable after resection; one inadequately treated patient had progressive disease (PD). Both PD patients died; one SD patient died during a seizure. Eleven germinoma patients are PF at median 66 months; one patient in CR refused RT, had PD at 10 months, received RT, and was PF at 56 months. Eleven of 14 nongerminomatous patients were PF at median 58 months. Conclusion. Response (germinoma, 91%; nongerminomatous, 55%) and survival are encouraging after this regimen plus response-based RT.

KW - Brain tumors

KW - Chemotherapy

KW - Germinoma

UR - http://www.scopus.com/inward/record.url?scp=33846906232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846906232&partnerID=8YFLogxK

U2 - 10.1002/pbc.20815

DO - 10.1002/pbc.20815

M3 - Article

VL - 48

SP - 285

EP - 291

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -